

CQ11-2 敗血症性 AKI の予防・治療目的に心房性ナトリウム利尿ペプチド(ANP)の投与は行うか？

検索データベース

- MEDLINE (PubMed/Ovid)
- CENTRAL
- 医学中央雑誌
- その他 ()

検索式とヒット数

PubMed search strategy (検索日 2019 年 5 月 9 日)

#1	"sepsis"[Mesh] OR "Shock, Septic"[Mesh] OR sepsis[tiab] OR (septic[tiab] AND shock[tiab])	175582
#2	seps*[tiab] OR septicem*[tiab] OR septicaem*[tiab] OR "blood stream infection"[tiab] OR endotoxi*[tiab]	148529
#3	"Systemic Inflammatory Response Syndrome"[mesh] OR "Systemic Inflammatory Response Syndrome" [tiab] OR "SIRS"[tiab]	123986
#4	"Multiple Organ Failure"[mesh] OR "MOF"[tiab] OR "organ failure"[tiab] OR "organ dysfunction"[tiab]	37414
#5	"Critical Illness"[Mesh] OR "Critical Care"[Mesh] OR "Intensive Care Units"[Mesh] OR stressed[tiab] OR "critically ill"[tiab] OR "critical care"[tiab] OR "intensive care"[tiab]	263008
#6	#1 OR #2 OR #3 OR #4 OR #5	481427
#7	"Acute Kidney Injury"[mesh]	43025
#8	acute kidney failure[tiab] OR acute renal failure[tiab]	23819
#9	acute kidney injur*[tiab] OR acute renal injur*[tiab]	19396
#10	acute kidney insufficie*[tiab] or acute renal insufficie*[tiab]	1758
#11	acute tubular necrosis [tiab]	3226
#12	ARI[tiab] OR AKI[tiab] or ARF[tiab] or AKF[tiab] or ATN[tiab]	24904
#13	#7 OR #8 OR #9 OR #10 OR #11 OR #12	72984
#14	#6 OR #13	541854
#15	("Atrial Natriuretic Factor"[Mesh] OR Atrial Natriuretic Factor[tiab] OR ANF[tiab])	16727
#16	Atrial Natriuretic Peptide*[tiab] OR ANP[tiab]	12912
#17	hANP [tiab]	662
#18	atriopeptin*[tiab]	570

#19	anaritide*[tiab]	20
#20	natriuretic*[tiab] AND (peptide*[tiab] OR factor*[tiab])	33119
#21	carperitide*[tiab]	116
#22	#15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21	37862
#23	randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR drug therapy[sh] OR randomly[tiab] OR trial[tiab] OR groups[tiab] NOT (animals [mh] NOT humans [mh])	3895055
#24	#14 AND #22 AND #23	469

CENTRAL search strategy (検索日 2019年 5月 9日)

#1	MeSH descriptor: [Sepsis] explode all trees	4028
#2	(sepsis):ti,ab,kw in Trials	10141
#3	MeSH descriptor: [Systemic Inflammatory Response Syndrome] explode all trees	4357
#4	(Systemic Inflammatory Response Syndrome):ti,ab,kw in Trials	1198
#5	(SIRS):ti,ab,kw in Trials	678
#6	MeSH descriptor: [Multiple Organ Failure] explode all trees	387
#7	(MOF):ti,ab,kw in Trials	141
#8	(MODS):ti,ab,kw in Trials	250
#9	MeSH descriptor: [Shock, Septic] explode all trees	784
#10	(septic):ti,ab,kw in Trials	4114
#11	(bacteremia OR endotoxemia OR septicemia):ti,ab,kw in Trials	3800
#12	(Pyemia OR Pyohemia):ti,ab,kw in Trials	6
#13	MeSH descriptor: [Critical Illness] explode all trees	1859
#14	MeSH descriptor: [Critical Care] explode all trees	1924
#15	MeSH descriptor: [Intensive Care Units] explode all trees	3288
#16	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15	22079
#17	MeSH descriptor: [Acute Kidney Injury] explode all trees	1214
#18	“acute kidney failure”:ti,ab,kw OR “acute renal failure”:ti,ab,kw in Trials	6525
#19	acute kidney injur*:ti,ab,kw OR acute renal injur*:ti,ab,kw in Trials	3455


#20	acute kidney insufficie*:ti,ab,kw OR acute renal insufficie*:ti,ab,kw in Trials	926
#21	acute tubular necrosis:ti,ab,kw in Trials	151
#22	ARF or AKF or ATN:ti,ab,kw in Trials	639
#23	#17 OR #18 OR #19 OR #20 OR #21 OR #22	8513
#24	MeSH descriptor: [Atrial Natriuretic Factor] explode all trees	858
#25	(atrial natriuretic factor*):ti,ab,kw in Trials	1326
#26	(ANF):ti,ab,kw in Trials	242
#27	(Atrial Natriuretic Peptide*):ti,ab,kw in Trials	1557
#28	(ANP):ti,ab,kw in Trials	889
#29	(anaritide*):ti,ab,kw in Trials	13
#30	(atriopeptin):ti,ab,kw in Trials	4
#31	(hANP):ti,ab,kw in Trials	94
#32	(carperitide):ti,ab,kw in Trials	57
#33	(natriuretic* AND (peptide* OR factor*)):ti,ab,kw in Trials	4834
#34	#24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33	5112
#35	#16 OR #23	29294
#36	#31 AND #32	419

医学中央雑誌 search strategy (検索日 2019年5月9日)

#1	(敗血症/TH or 敗血症/TA or セプシス/TA or sepsis/TA) and (PT=会議録除く)	22679
#2	(ショック-敗血症性/TH or 敗血症性ショック/TA or "septic shock"/TA) and (PT=会議録除く)	6282
#3	(全身性炎症反応症候群/TH or 全身性炎症反応症候群/TA or "systemic inflammatory response syndrome"/TA or SIRS/TA) and (PT=会議録除く)	18008
#4	(多臓器不全/TH or 多臓器不全/TA or 多臓器障害/TA or 多臓器機能不全/TA or 多臓器機能障害/TA or "organ failure"/TA or "organ dysfunction"/TA or MOF/TA or MODS/TA) and (PT=会議録除く)	8061
#5	(内毒素血症/TH or エンドトキシン血症/TA)) and (PT=会議録除く)	697
#6	#1 OR #2 OR #3 OR #4 OR #5	30860

#7	(急性腎障害/TH or 急性腎障害/TA or 急性腎傷害/TA or 急性腎不全/TA) and (PT=会議録除く)	10006
#8	(尿細管壊死-急性/TH or 急性尿細管壊死/TA) and (PT=会議録除く)	467
#9	#7 OR #8	10133
#10	("Atrial Natriuretic Factor"/TH or ANP/TA or ANF/AL or hANP/TA or 心房性ナトリウム利尿ペプチド/TA) and (PT=会議録除く)	7631
#11	(Anaritide/TH or アナリチド/TA) and (PT=会議録除く)	1
#12	(Carperitide/TH or アトリオペプチン/TA or ハンプ/TA or カルペリチド/TA) and (PT=会議録除く)	886
#13	#10 OR #11 OR #12	7794
#14	(ランダム化比較試験/TH or 準ランダム化比較試験/TH or ランダム化/AL or 無作為化/AL or 比較試験/AL or 臨床試験/AL or プラゼボ/AL or 対照/AL or コントロール/AL or 臨床研究/AL) and (PT=会議録除く)	228798
#15	#6 OR #9	39966
#16	#13 AND #14 AND #15	31

PRISMA フロー図




Risk of Bias サマリー

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Allgren 1997	+	+	+	+	+	+	-
Lewis 2000	+	+	+	+	+	+	?
Rahman 1994	+	?	-	+	+	?	+


フォレストプロット

アウトカム① 死亡率


Study or Subgroup	ANP		Control		Weight	Risk Ratio M-H, Random, 95% CI	Year
	Events	Total	Events	Total			
Rahman 1994	5	30	8	23	5.0%	0.48 [0.18, 1.27]	1994
Allgren 1997	73	248	67	256	40.9%	1.12 [0.85, 1.49]	1997
Lewis 2000	65	108	64	114	54.1%	1.07 [0.86, 1.34]	2000
Total (95% CI)		386		393	100.0%	1.05 [0.84, 1.31]	
Total events	143		139				
Heterogeneity: Tau ² = 0.01; Chi ² = 2.72, df = 2 (P = 0.26); I ² = 27%							
Test for overall effect: Z = 0.43 (P = 0.67)							




アウトカム② 腎代替療法



アウトカム③ AKIからの回復





アウトカム④ 低血圧



ファンネルプロット

① 死亡率

② 腎代替療法



② ΔKIからの回復

① 低血圧

